Glad to see today's RNS confirm success in initial production for the Aurora+FLT3 programme and plans for future upscaling. It shows they have faith in Sareum's programme at Hebei Medical University over there in Shijiazhuang, and with their record of success in bringing drugs into the clinic they will be progressing the application for first-in-human trials in China with diligence. I look forward to their commencement being announced in the coming period.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.